The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
This will dramatically improve timely intervention with the right experts thus ensuring significant improvement in patient’s condition management and health outcome
DKSH has signed an agreement to acquire two ear care brands from Noru Pharma for Australia, New Zealand, and selected markets in Asia.
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Subscribe To Our Newsletter & Stay Updated
